Loading Events

Past Events

Events Search and Views Navigation

Event Views Navigation

June 2020

NIH R01 Cycles

June 5
|Recurring Event (See all)

One event on June 5, 2020 at 12:00 am

One event on October 5, 2020 at 12:00 am

Biobehavioral and Technological Interventions to Attenuate Cognitive Decline in Individuals with Cognitive Impairment or Dementia (R01 Clinical Trial Optional):
The purpose of this funding opportunity announcement (FOA) is to stimulate clinical research focused on biobehavioral or technological interventions to attenuate cognitive decline in individuals with dementia (such as Alzheimer’s disease, Lewy body dementia, vascular dementia), mild cognitive impairment (MCI), or disease- or age-related cognitive decline. Application budgets are not limited but need to reflect the actual needs of the proposed project.

High Throughput Screening (HTS) to Discover Chemical Probes:
Encourages investigators to form collaborations with an established academic, nonprofit, or commercial high throughput screening (HTS) facility that has the requisite expertise and experience to implement HTS-ready assays for the discovery and development of small molecule chemical probes. Application budgets are not limited but need to reflect the actual needs of the proposed project.

Preclinical Research on Model Organisms to Predict Treatment Outcomes for Disorders Associated with Intellectual and Developmental Disabilities:
Encourages applications from institutions/ organizations addressing preclinical research in model organisms of neurodevelopmental disorders. Budgets for direct costs of up to $499,999 per year may be requested.

Pregnancy in Women with Disabilities:
This FOA issued by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) encourages research project grants (R01) investigating the incidence, course, and outcomes of pregnancy among women with disabilities. Application budgets are not limited but need to reflect the actual needs of the proposed project.

Prevention Research in Mid-Life Adults (R01 Clinical Trial Optional):
This Funding Opportunity Announcement (FOA) seeks to stimulate research on mid-life adults (those 50 to 64 years of age) that can inform efforts to optimize health and well-being as individuals age and prevent illness and disability in later years.Application budgets are not limited but need to reflect the actual needs of the proposed project.

Promoting Research in Basic Neuroscience (R01 Clinical Trial Not Allowed):
he goal of this Funding Opportunity Announcement (FOA) is to stimulate research addressing fundamental questions in basic neuroscience. Application budgets are not limited but need to reflect the actual needs of the proposed project.

Find out more »

96th Annual Meeting of the American Association of Neuropathologists

June 11 - June 14
Hyatt Regency Monterey, 1 Old Golf Course Roadf
Monterey, CA 93940-4908 United States

The AANP is proud to be the only association exclusively focused on the clinical and scientific practice of neuropathology in the United States. During the first week of every June, AANP provides cutting-edge educational sessions led by the nation’s preeminent neuropathologists at their Annual Meeting. The meeting includes a one-day Special Course, which features two “What Every Neuropathologist Needs to Know” sessions, two days of scientific sessions (platform and poster), an evening Diagnostic Slide Session, and a half-day Presidential Symposium.

Find out more »

July 2020

Cycle 1: Alzheimer’s Drug Discovery Foundation

July 10
|Recurring Event (See all)

One event on July 10, 2020 at 12:00 am

One event on October 9, 2020 at 12:00 am

LOI Due Dates:

  • Cycle 1: April 10, 2020
  • Cycle 2: July 10, 2020
  • Cycle 3: October 9, 2020

Drug Development Program
The goal of this RFP is to develop therapeutics for Alzheimer’s disease and related dementias. This RFP focuses on building preclinical evidence in animal models and on advancing lead molecules to the clinical candidate selection stage. Average Award: Up to $600,000 based on stage and scope of research.
Program to Accelerate Clinical Trials (PACT)
The goal of this RFP is to increase the number of innovative pharmacologic interventions tested in clinical studies for Alzheimer’s disease and related dementias. Average Award: Up to $3,000,000 based on stage and scope of research. For studies requiring additional support, co-funding from other funding agencies or investors is encouraged.
Neuroimaging and CSF Biomarker Development Prgram
The aim of this RFP is to develop biomarkers for which there is a clear clinical need in Alzheimer’s disease and related dementias. Average award: Up to $600,000 based on stage and scope of research.
Prevention Beyond the Pipeline
The ADDF seeks to support comparative effectiveness research, prevention clinical trials, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline. Average awards: $50,000-$100,000 for epidemiological analyses, and u to $3,000,000 for clinical trials based on stage and scope of research.

Find out more »

FENS Forum of Neuroscience 2020

July 11 - July 15
SEC Center, Exhibition Way
Glasgow, G3 8YW United Kingdom

The FENS Forum of Neuroscience is Europe’s largest international neuroscience meeting. The Forum scientific programme covers all domains in modern brain research. With 56 parallel symposia, more than 3,500 abstracts and 20 plenary and special lectures, the FENS Forum covers neuroscience from basic to translational research.

Find out more »

Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)

July 12
|Recurring Event (See all)

One event on January 10, 2021 at 12:00 am

Sponsor: National Institutes of Health (multiple Institutes)
LOI Due Date: July 12, 2020, January 10, 2021
Application Due Date: August 11, 2020, February 9, 2021
Award: Application budgets are not limited but must reflect the actual needs of the proposed project. Applicants should rarely exceed up to $500,000 total cost per year for Phase I and up to $1,500,000 total cost per year for the Phase II. The Blueprint Neurotherapeutics Network (BPN) encourages applications from small businesses seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories.

Find out more »

CREATE Bio Development Track: Nonclinical and Early-Phase Clinical Development for Biologics (U44 Clinical Trial Optional)  

July 20

Sponsor: National Institutes of Health (NIH)
Due Date: July 20, 2020
Award: This Funding Opportunity Announcement (FOA) supports the development of therapeutic Biotechnology Products and Biologics (e.g., peptides, proteins, oligonucleotides, gene therapies, cell therapies, and novel emerging therapies) for disorders identified under the NINDS mission. Application budgets are not limited but must reflect the actual needs of the proposed project. Typical budgets for these projects will normally remain less than or equal to $1,000,000 per year in total cost for U44 Phase I and $1,500,000 per year in total cost for U44 Phase II.

Find out more »

CREATE Bio Development Track: Nonclinical and Early-Phase Clinical Development for Biologics (U01 Clinical Trial Optional)

July 20

Sponsor: National Institutes of Health (NIH)
Due Date: July 20, 2020
Award: This Funding Opportunity Announcement (FOA) supports the development of therapeutic Biotechnology Products and Biologics (e.g., peptides, proteins, oligonucleotides, gene therapies, cell therapies, and novel emerging therapies) for disorders identified under the NINDS mission. Application budgets are not limited but must reflect the actual needs of the proposed project. Applications should rarely exceed $1,000,000 in direct costs per year unless during the optional clinical trial phase in which up to $1,500,000 in direct costs per year may be justified.

Find out more »

September 2020

Arnold O. Beckman Postdoctoral Fellowship

September 4

Sponsor: Arnold and Mabel Beckman Foundation
Due Date: September 4, 2020
Award: Fellows will be appointed for two years, with possibility for third year by renewal. Fellows will begin in July of program year. The award amount is $180,000 over 2 years for salary, fringe benefits and research expenditures; instrumentation fellowships will receive an additional one-time amount of up to $100,000. Fellows receiving year 3 renewal award will receive additional $90,000.

Find out more »

NIH R43/44 and U43/44

September 5
|Recurring Event (See all)

One event on January 5, 2021 at 12:00 am

One event on April 5, 2021 at 12:00 am

Sponsor: National Institutes of Health
DUE DATES: (same every year)

  • Cycle 1: Jan 5
  • Cycle 2: April 5
  • Cycle 3: September 5

BRAIN Initiative: Development Optimization, and Validation of Novel Tools and Technologies for Neuroscience Research (SBIR) (R43/R44 – Clinical Trial Not Allowed): The purpose of this funding opportunity announcement (FOA) is to support the development of novel tools and technologies through the Small Business Technology Transfer (STTR) program to advance the field of neuroscience research. According to statutory guidelines, total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards.

Find out more »

ISHCSF Hydrocephalus 2020

September 11 - September 14
Clarion Hotel Post, Drottningtorget 10
Göteborg, 411 03 Sweden

This Annual Meeting, is the largest worldwide dedicated to research into hydrocephalus and related disorders and takes place each year since 2008 around the month of September in a different city. This Meeting is a consistent international scientific assembly and forum bridging the junior and senior, the clinical and basic scientists interested in the fascinating and multidisciplinary field of CSF disorders, bringing together neurologists, neurosurgeons, researchers and professionals among others to the potential benefit of patients and families.

Find out more »

BRAIN Initiative: Clinical Studies to Advance Next-Generation Invasive Devices for Recording and Modulation in the Human Central Nervous System (UH3)

September 21
|Recurring Event (See all)

One event on September 21, 2020 at 12:00 am

Sponsor: National Institutes of Health
LOI Due Dates: May 23, 2020, September 21, 2020
Application Deadlines: June 22, 2020, October 21, 2020
Award: The NIH anticipates providing $10M per year to fund an estimated 5 to 7 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. Budgets should rarely exceed $2M per year.The purpose of this Funding Opportunity Announcement (FOA) is to encourage investigators to pursue a small clinical trial to obtain critical information necessary to advance recording and/or stimulating devices to treat central nervous system disorders and better understand the human brain (e.g., Early Feasibility Study).

Find out more »

AES Research and Training Workshops

September 23
|Recurring Event (See all)

One event on September 23, 2020 at 12:00 am

Sponsor: American Epilepsy Society
Due Dates: 

  • Cycle 1: May 4, 2020
  • Cycle 2: September 23, 202o

Award: AES welcomes applications for funding to support scientific conferences and workshops focused on epilepsy research and training. Applications for workshop funding are reviewed by the AES Research and Training Council, and the number and amount of awards made each year are contingent on available funds.

Find out more »

AES Seed Grant Program 

September 28
|Recurring Event (See all)

One event on September 28, 2020 at 12:00 am

Sponsor: American Epilepsy Society
Due Dates: 

  • Cycle 1: May 4, 2020
  • Cycle 2: September 28, 2020

Award: The AES Seed Grant Program provides support to established investigators to pursue new and innovative directions in epilepsy research, bring new research methods to their research programs, or begin new collaborations with other investigators in epilepsy or in different, complementary disciplines. Seed Grants may provide up to $20,000 for one year for direct costs only, and they may not be renewed.

Find out more »

Broad PCORI Funding Announcements

September 29

Sponsor: Patient-Centered Outcomes Research Institute
LOI Due Date: September 29, 2020 at 5pm ET
Application Due Date: January 12, 2021 at 5pm ET
Award: The Broad PCORI Funding Announcements (PFAs) seek investigator-initiated applications for patient-centered comparative clinical effectiveness research (CER) projects aligned with our priority areas for research

Find out more »

October 2020

NIH R01 Cycles

October 5
|Recurring Event (See all)

One event on June 5, 2020 at 12:00 am

One event on October 5, 2020 at 12:00 am

Biobehavioral and Technological Interventions to Attenuate Cognitive Decline in Individuals with Cognitive Impairment or Dementia (R01 Clinical Trial Optional):
The purpose of this funding opportunity announcement (FOA) is to stimulate clinical research focused on biobehavioral or technological interventions to attenuate cognitive decline in individuals with dementia (such as Alzheimer’s disease, Lewy body dementia, vascular dementia), mild cognitive impairment (MCI), or disease- or age-related cognitive decline. Application budgets are not limited but need to reflect the actual needs of the proposed project.

High Throughput Screening (HTS) to Discover Chemical Probes:
Encourages investigators to form collaborations with an established academic, nonprofit, or commercial high throughput screening (HTS) facility that has the requisite expertise and experience to implement HTS-ready assays for the discovery and development of small molecule chemical probes. Application budgets are not limited but need to reflect the actual needs of the proposed project.

Preclinical Research on Model Organisms to Predict Treatment Outcomes for Disorders Associated with Intellectual and Developmental Disabilities:
Encourages applications from institutions/ organizations addressing preclinical research in model organisms of neurodevelopmental disorders. Budgets for direct costs of up to $499,999 per year may be requested.

Pregnancy in Women with Disabilities:
This FOA issued by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) encourages research project grants (R01) investigating the incidence, course, and outcomes of pregnancy among women with disabilities. Application budgets are not limited but need to reflect the actual needs of the proposed project.

Prevention Research in Mid-Life Adults (R01 Clinical Trial Optional):
This Funding Opportunity Announcement (FOA) seeks to stimulate research on mid-life adults (those 50 to 64 years of age) that can inform efforts to optimize health and well-being as individuals age and prevent illness and disability in later years.Application budgets are not limited but need to reflect the actual needs of the proposed project.

Promoting Research in Basic Neuroscience (R01 Clinical Trial Not Allowed):
he goal of this Funding Opportunity Announcement (FOA) is to stimulate research addressing fundamental questions in basic neuroscience. Application budgets are not limited but need to reflect the actual needs of the proposed project.

Find out more »

Cycle 1: Alzheimer’s Drug Discovery Foundation

October 9
|Recurring Event (See all)

One event on July 10, 2020 at 12:00 am

One event on October 9, 2020 at 12:00 am

LOI Due Dates:

  • Cycle 1: April 10, 2020
  • Cycle 2: July 10, 2020
  • Cycle 3: October 9, 2020

Drug Development Program
The goal of this RFP is to develop therapeutics for Alzheimer’s disease and related dementias. This RFP focuses on building preclinical evidence in animal models and on advancing lead molecules to the clinical candidate selection stage. Average Award: Up to $600,000 based on stage and scope of research.
Program to Accelerate Clinical Trials (PACT)
The goal of this RFP is to increase the number of innovative pharmacologic interventions tested in clinical studies for Alzheimer’s disease and related dementias. Average Award: Up to $3,000,000 based on stage and scope of research. For studies requiring additional support, co-funding from other funding agencies or investors is encouraged.
Neuroimaging and CSF Biomarker Development Prgram
The aim of this RFP is to develop biomarkers for which there is a clear clinical need in Alzheimer’s disease and related dementias. Average award: Up to $600,000 based on stage and scope of research.
Prevention Beyond the Pipeline
The ADDF seeks to support comparative effectiveness research, prevention clinical trials, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline. Average awards: $50,000-$100,000 for epidemiological analyses, and u to $3,000,000 for clinical trials based on stage and scope of research.

Find out more »

NIH R21, R03

October 16
|Recurring Event (See all)

One event on February 16, 2021 at 12:00 am

One event on October 16, 2021 at 12:00 am

Sponsor: National Institute of Health 
DUE DATES: 

  • Cycle 3: October 16, 2020 by 5 PM of local organization time
  • Cycle 1: February 16, 2021 by 5 PM of local organization time
  • Cycle 2: June 16, 2021 by 5 PM of local organization time

Biobehavioral and Technological Interventions to Attenuate Cognitive Decline in Individuals with Cognitive Impairment or Dementia: 
The combined budget for direct costs for the two-year project period may not exceed $275,000.  No more than $200,000 may be requested in any single year.
Small Research Grants for Analyses of Gabriella Miller Kids First Pediatric Research Data (R03 Clinical Trial Not Allowed)
The combined budget for direct costs for the two year project period may not exceed $200,000.
Biobehavioral and Technological Interventions to Attenuate Cognitive Decline in Individuals with Cognitive Impairment or Dementia (R21)
The combined budget for direct costs for the two-year project period may not exceed $275,000.  No more than $200,000 may be requested in any single year.
Chronic Condition Self-Management in Children and Adolescents (R21 Clinical Trial Optional)
Direct costs are limited to $275,000 over an R21 two-year period, with no more than $200,000 in direct costs allowed in any single year.

Find out more »

BRAIN Initiative: New Concepts and Early – Stage Research for Large – Scale Recording and Modulation in the Nervous System (R21 Clinical Trial Not Allowed)

October 29
|Recurring Event (See all)

One event on October 29, 2020 at 12:00 am

Sponsor: National Institutes of Health
Application Deadlines:  May 1, 2020, October 29, 2020
Award: NIH intends to fund an estimated 10-15 awards per fiscal year, corresponding to a total of $5 million over the two-year project period. The combined direct cost budget for the two-year project period may not exceed $300,000. No more than $200,000 may be requested in any single year. A central goal of the BRAIN Initiative is to understand how electrical and chemical signals code information in neural circuits and give rise to sensations, thoughts, emotions and actions

Find out more »

November 2020

Global Brain and Nervous System Disorders Research Across the Lifespan (R21 Clinical Trial Optional)

November 6

Sponsor: National Institutes of Health
Due Date: November 6, 2020
Award: This Funding Opportunity Announcement (FOA) encourages exploratory/developmental research grant applications, proposing the development of innovative, collaborative research projects on brain and other nervous system function and disorders throughout life, relevant to low- and middle-income countries (LMICs). Application budgets are limited to $125,000 per year in direct costs, but must reflect the actual needs of the proposed project.

Find out more »

ISPN 2020 Virtual Meeting

November 6

We have planned a 3-day meeting of 4 hours/day to cover some of the most pressing and exciting topics in pediatric neurosurgery today, and have assembled global leaders in several of pediatric neurosurgery’s subspecialties to deliver what promises to be the most exciting, illuminating, and instructive meeting in this year’s calendar.

Find out more »
+ Export Events